CN104968664A - 作为酪氨酸激酶抑制剂的并环化合物 - Google Patents
作为酪氨酸激酶抑制剂的并环化合物 Download PDFInfo
- Publication number
- CN104968664A CN104968664A CN201380072466.6A CN201380072466A CN104968664A CN 104968664 A CN104968664 A CN 104968664A CN 201380072466 A CN201380072466 A CN 201380072466A CN 104968664 A CN104968664 A CN 104968664A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- amino
- yue
- hydrogen atom
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
本发明涉及通式(I)所示的化合物,制备所述化合物的方法,含有所述化合物的药物组合物,以及所述化合物在制备用于预防和/或治疗B细胞相关的血癌、炎性以及自身免疫性疾病的药物中的应用,其中X、W、环A、环B、L1、L2、R1、R2、R3、
Description
PCT国内申请,说明书已公开。
Claims (1)
- PCT国内申请,权利要求书已公开。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380072466.6A CN104968664A (zh) | 2012-12-12 | 2013-12-12 | 作为酪氨酸激酶抑制剂的并环化合物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210534945 | 2012-12-12 | ||
CN201210534945.2 | 2012-12-12 | ||
CN201380072466.6A CN104968664A (zh) | 2012-12-12 | 2013-12-12 | 作为酪氨酸激酶抑制剂的并环化合物 |
PCT/CN2013/001555 WO2014089913A1 (zh) | 2012-12-12 | 2013-12-12 | 作为酪氨酸激酶抑制剂的并环化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104968664A true CN104968664A (zh) | 2015-10-07 |
Family
ID=50933758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380072466.6A Pending CN104968664A (zh) | 2012-12-12 | 2013-12-12 | 作为酪氨酸激酶抑制剂的并环化合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104968664A (zh) |
WO (1) | WO2014089913A1 (zh) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
BR112014030812B1 (pt) | 2012-06-13 | 2022-11-08 | Incyte Holdings Corporation | Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
SG10201708520YA (en) | 2013-04-19 | 2017-12-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
JP7402804B2 (ja) | 2018-02-01 | 2023-12-21 | マイオカーディア,インク | ピラゾール化合物及びその調製 |
KR20210018265A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 고체 형태 및 이의 제조 방법 |
SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
US11066404B2 (en) * | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP4013750A1 (en) | 2019-08-14 | 2022-06-22 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
US20230027026A1 (en) * | 2019-09-27 | 2023-01-26 | Jubilant Biosys Limited | Fused pyrimidine compounds, compositions and medicinal applications thereof |
EP4041731A1 (en) | 2019-10-11 | 2022-08-17 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Fgfr阻害剤としての二環式複素環 |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
EP4069695A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Derivatives of an fgfr inhibitor |
AU2021262482A1 (en) | 2020-04-28 | 2023-01-05 | Iomx Therapeutics Ag | Bicyclic kinase inhibitors and uses thereof |
CN113801139A (zh) * | 2020-06-12 | 2021-12-17 | 华东理工大学 | 作为rsk抑制剂的嘧啶并恶嗪衍生物及其应用 |
WO2022072632A1 (en) * | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
CN112457268A (zh) * | 2020-12-11 | 2021-03-09 | 平江县吉成科技有限责任公司 | 一种温和的4-氨基异恶唑盐酸盐的合成方法 |
WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1582146A (zh) * | 2001-12-14 | 2005-02-16 | 应用研究***Ars股份公司 | 用非多肽环-磷酸腺苷水平调节剂诱导***的方法 |
CN1675214A (zh) * | 2002-08-14 | 2005-09-28 | 霍夫曼-拉罗奇有限公司 | 具有抗增殖活性的嘧啶并化合物 |
US20050215575A1 (en) * | 2003-07-16 | 2005-09-29 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
CN102083800A (zh) * | 2008-06-27 | 2011-06-01 | 阿维拉制药公司 | 杂芳基化合物和其用途 |
CN102816162A (zh) * | 2011-06-10 | 2012-12-12 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006516561A (ja) * | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての2−アミノピリジン置換ヘテロ環類 |
PL1713806T3 (pl) * | 2004-02-14 | 2013-09-30 | Irm Llc | Związki i kompozycje jako inhibitory kinaz białkowych |
-
2013
- 2013-12-12 WO PCT/CN2013/001555 patent/WO2014089913A1/zh active Application Filing
- 2013-12-12 CN CN201380072466.6A patent/CN104968664A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1582146A (zh) * | 2001-12-14 | 2005-02-16 | 应用研究***Ars股份公司 | 用非多肽环-磷酸腺苷水平调节剂诱导***的方法 |
CN1675214A (zh) * | 2002-08-14 | 2005-09-28 | 霍夫曼-拉罗奇有限公司 | 具有抗增殖活性的嘧啶并化合物 |
US20050215575A1 (en) * | 2003-07-16 | 2005-09-29 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
CN102083800A (zh) * | 2008-06-27 | 2011-06-01 | 阿维拉制药公司 | 杂芳基化合物和其用途 |
CN102816162A (zh) * | 2011-06-10 | 2012-12-12 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
Non-Patent Citations (2)
Title |
---|
SHAOHUA CHANG等,: ""Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant"", 《J. MED. CHEM.》 * |
SHILIN XU等,: ""Design, Synthesis, and Biological Evaluation of 2‑Oxo-3,4-dihydropyrimido[4,5‑d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties"", 《J. MED. CHEM.》 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014089913A1 (zh) | 2014-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104968664A (zh) | 作为酪氨酸激酶抑制剂的并环化合物 | |
JP7082130B2 (ja) | Tyk2阻害剤およびその使用 | |
AU2017246452B2 (en) | MDM2 protein degraders | |
EP2376478B1 (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
CN104583195B (zh) | 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物 | |
KR101560066B1 (ko) | 테트라히드로-피리도-피리미딘 유도체 | |
TWI744225B (zh) | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 | |
WO2020084305A1 (en) | Bicyclic peptide ligands and uses thereof | |
EP3500569B1 (en) | 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof | |
JP7352284B2 (ja) | LSD-1インヒビターとしてのピロロ〔2,3-c〕ピリジン及び関連類似体 | |
CA2908098A1 (en) | Mk2 inhibitors and uses thereof | |
CN102918045A (zh) | 作为蛋白激酶抑制剂的取代的吡咯并三嗪 | |
TWI707855B (zh) | 咪唑并嗒類化合物及其用途 | |
WO2021050992A1 (en) | Usp30 inhibitors and uses thereof | |
JP2024506909A (ja) | Hpk1アンタゴニスト及びその使用 | |
KR20090007391A (ko) | 키나제 억제제로서의 3-비치환된 N-(아릴- 또는 헤테로아릴)-피라졸로[1,5-a]피리미딘 | |
CA3091202A1 (en) | Chromene derivatives as inhibitors of tcr-nck interaction | |
CN108137580A (zh) | 作为激酶抑制剂的稠合的吡啶衍生物 | |
CN116249696A (zh) | 嘧啶酮类化合物及其用途 | |
TW202342013A (zh) | 雜環化合物、其組成物及用其進行治療之方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 250101 Shandong city of Ji'nan province high tech Zone Hong Xing three North Road No. 2 building 401 Ji'nan trough Applicant after: Shandong Henry Medical Science and Technology Co., Ltd. Address before: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 University Science Park B302 Applicant before: Shandong Henry Medical Science and Technology Co., Ltd. |
|
COR | Change of bibliographic data | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151007 |
|
WD01 | Invention patent application deemed withdrawn after publication |